The United States Food and Drug Administration (FDA) is rethinking its rules on what kind of information pharma companies can share with physicians regarding off-label use of their products. That’s good news for the practice of medicine.
At the moment, pharma company employees can talk about a drug only in the context of the condition indicated in its FDA-approved label. Anything they say about another, unapproved use of the drug is considered “misbranding” according to federal law, and subjects the company to civil and criminal prosecution. [Read more…] about Scientific Exchange Calls for Some Talk of “Off-Label” Use